SOPHIA ANTIPOLIS, France, March 3 /PRNewswire-FirstCall/ — NicOx S.A. Euronext: COX Paris: COX today announced its financial results for 2007 and provided an overview of its activities during the year. NicOx also announced today the initiation of Read More

CHICAGO, July 29, 2008 – Elan Corporation, plc (NYSE: ELN) and Wyeth (NYSE: WYE) today are presenting detailed results from the companies’ 18-month Phase 2 study of bapineuzumab (AAB-001) in patients with mild to moderate Alzheimer’s disease at Read More

Elan Corporation, plc ELN and Wyeth WYE today are presenting detailed results from the companies ’ 18-month Phase 2 study of bapineuzumab (AAB-001) in patients with mild to moderate Alzheimer’s disease at the Alzheimer ’ s Association ’ s Read More

This entry was posted on Thursday, July 31st, 2008 at 12:31 pm and is filed under primary pulmonary hypertension. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.